Topic: Chutes and Ladders
Alder hires Juno exec as CEO, Allergan brings in Abbott vet after investors demand change, and ResTORbio poaches Novartis researcher as clinical VP.
GlaxoSmithKline’s former head of dermatology R&D, David Gordon, has joined Aclaris Therapeutics as its new chief medical officer.
Alder BioPharmaceuticals poached Juno’s COO to lead the company, as it preps to submit its migraine treatment for FDA approval and heavy competition.
Celgene's shake-ups continue with new CFO, Zai Lab grabs top AZ exec, Axovant brings on Spark co-founder as CTO, and Gilead promotes its top dealmaker.
Sarepta brought on Biogen’s VP of late-stage programs, Gilmore O’Neill, as chief medical officer, after their previous hire left after 8 months.
Curt Herberts, who spearheaded a number of deals as Sangamo Therapeutics' chief business officer, is joining Senti Bio as its new CFO and CBO.
Novartis' ex-oncology head jumps to startup; Axovant poaches Allergan's CMO; and Biogen brings on Pfizer dealmaker.
After settling a legal scuffle with its ex-CEO Joseph Payne and appointing four new board members, Arcturus reinstated Payne in his old role.
ResearchPoint Global brought on José Iglesias as medical director for oncology to help develop the CRO’s strategy for cancer-focused sponsors.
James Pennington joined AzurRx BioPharma as CMO as the company aims to launch a phase 2 trial of its lead candidate in cystic fibrosis this year.